ClinicalTrials.Veeva

Menu

Biomarkers to Predict Acute Respiratory Distress Syndrome(ARDS) in Patients With Sepsis

S

Shandong University

Status

Enrolling

Conditions

Sepsis

Treatments

Other: ALDH2 rs671 mutation

Study type

Observational

Funder types

Other

Identifiers

NCT05914428
2020BIPROSALDH2

Details and patient eligibility

About

Sepsis-induced acute respiratory distress syndrome (ARDS) is a life-threatening acute inflammatory lung injury, associated with increased pulmonary microvascular permeability, increased lung weight, and loss of aerated lung tissue.Despite advances in critical care, no established and targeted treatment for ARDS, contributing to a persistently high mortality rate of 34% to 45%. Therefore, exploring novel therapeutic targets for septic ARDS is of paramount importance.Acetaldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme that serves as the primary toxic aldehyde scavenger and is expressed in various cells, including neutrophils. The ALDH2 rs671 single nucleotide polymorphism, leading to an approximate 90% decrease in ALDH2 enzymatic activity, is implicated in occurrence of macrovascular conditions, such as coronary artery disease, pulmonary arterial hypertension, and aortic aneurysm or dissection.An array of studies has delved into role of ALDH2 in regulating cellular processes, including inflammation, autophagy, apoptosis, necrosis,efferocytosis and pyroptosis.but whether it associated with the incidence of septic-ARDS remains unknown.The aim of this study was to determine whether the ALDH2 rs671 single nucleotide polymorphism was associated with the incidence of septic-ARDS.

Enrollment

170 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients admitted to the ICU who were aged 18 to 85 years with a diagnosis of sepsis.Sepsis was assessed according to the third international consensus definition as life-threatening organ dysfunction caused by a dysregulated host response to infection; organ dysfunction was defined as an acute change in total Sequential Organ Failure Assessment (SOFA) score of ≥2 points consequent to the infection.

Exclusion criteria

  1. interstitial lung disease, chronic obstructive pulmonary disease or congestive heart failure;
  2. nerve injury or disease with likely prolonged ventilation;
  3. the use of long-term oxygen therapy or noninvasive ventilation at home;
  4. pregnancy or breastfeeding.

Trial design

170 participants in 1 patient group

sepsis
Description:
We selected blood samples from sepsis patients from the biological bank of Qilu hospital.The ALDH2 genotype (rs671) was detected in these septic patients and divided into ALDH2 wild-type ,ALDH2 rs671 mutation.
Treatment:
Other: ALDH2 rs671 mutation

Trial contacts and locations

1

Loading...

Central trial contact

Jiaojiao Pang, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems